EUVIMEDEUVIMED entdecken
Crossref

Toxicological Evaluation of the Sweet Protein Brazzein Derived From Komagataella phaffii for Use as a Sweetener in Foods and Beverages

Jwar Meetro iD, Labiba Nahian, Kirt R Phipps iD, Trung Duc Vo, Irina Dahms, Minal Lalpuria, Hadi Omrani

Journal of Applied Toxicology · 2025

DOI: 10.1002/jat.4811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2025. Verfasst von Jwar Meetro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Intertek Health Sciences Inc, Mississauga, Ontario, Canada. Hauptthemen laut MEDLINE: Sweetening Agents, Plant Proteins, Beverages. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Sweegen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brazzein is a promising new protein sweetener that has gained significant attention by the food and beverage industry in recent years. Brazzein has a sweetness intensity significantly greater than that of other low‐ and no‐calorie sweeteners currently on the global market and can provide a comparable sweetness at lower use levels within food and beverage products. In this study, a safety assessment of the sweet protein brazzein, produced from the fermentation of Komagataella phaffii , was undertaken in an in vitro digestibility study, an in silico allergenicity assessment, an in vitro reverse mutation assay, an in vitro mammalian micronucleus assay, and a 90‐day oral toxicity study in rats. The results of the in silico and in vitro studies indicate that brazzein is not readily digestible, does not have allergenic potential, and does not have genotoxic or mutagenic potential. In the 90‐day toxicity study, brazzein was not associated with any adverse systemic effects at up to 2000 mg/kg body weight/day, the highest dose tested. The dose of 2000 mg/kg body weight/day was concluded to be the no observed adverse effect level. The findings from the current safety assessment demonstrate that brazzein is safe for use as a sweetener in foods and beverages for human consumption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sweetening AgentsPlant ProteinsBeveragesAnimalsMaleRatsFemaleMicronucleus TestsRats, Sprague-DawleyNo-Observed-Adverse-Effect LevelMutagenicity TestsDose-Response Relationship, Drug

Stichwörter der Autor:innen

allergenicitybrazzeingenotoxicityrisk assessmentsweetenertoxicology

Substanzen

Sweetening AgentsPlant Proteinsbrazzein protein, Pentadiplandra brazzeana

Autor:innen und Institutionen

  • Intertek Health Sciences Inc, Mississauga, Ontario, Canada.
  • Intertek Health Sciences Inc, Farnborough, Hampshire, UK.
  • The Coca-Cola Company, Atlanta, Georgia, USA.
  • Sweegen Inc, Foothill Ranch, California, USA.

ORCID-Profile: Jwar Meetro, Kirt R Phipps

Förderung

  • Sweegen Inc

Zitieren

APA

Meetro, J., Nahian, L., Phipps, K. R., Vo, T. D., Dahms, I., Lalpuria, M., & Omrani, H. (2025). Toxicological Evaluation of the Sweet Protein Brazzein Derived From Komagataella phaffii for Use as a Sweetener in Foods and Beverages. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4811

Vancouver

Meetro J, Nahian L, Phipps KR, Vo TD, Dahms I, Lalpuria M, et al. Toxicological Evaluation of the Sweet Protein Brazzein Derived From Komagataella phaffii for Use as a Sweetener in Foods and Beverages. Journal of Applied Toxicology. 2025. doi:10.1002/jat.4811

BibTeX
@article{Meetro2025,
  author = {Meetro, Jwar and Nahian, Labiba and Phipps, Kirt R and Vo, Trung Duc and Dahms, Irina and Lalpuria, Minal and Omrani, Hadi},
  title = {Toxicological Evaluation of the Sweet Protein Brazzein Derived From Komagataella phaffii for Use as a Sweetener in Foods and Beverages},
  journal = {Journal of Applied Toxicology},
  year = {2025},
  doi = {10.1002/jat.4811}
}
Kostenlos starten →